
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1019 | 983 | 961 | 1303 | 1560 | 1971 |
Fund Return | 1.9% | -1.7% | -3.95% | 9.23% | 9.3% | 7.02% |
Place in category | 31 | 7 | 143 | 4 | 5 | 34 |
% in Category | 22 | 7 | 81 | 3 | 3 | 32 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Fidelity 500 Index Institutional Pr | 593.97B | -4.92 | 12.17 | 12.31 | ||
Fidelity Contrafund | 133.44B | -3.29 | 18.13 | 14.54 | ||
Fidelity Total Market Index Instl b | 99.37B | -5.52 | 11.34 | 11.61 | ||
Fidelity International Index Inst | 58.83B | 12.35 | 10.69 | 5.65 | ||
Fidelity Blue Chip Growth | 54.71B | -12.53 | 16.00 | 16.01 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Vanguard Health Care Adm | 32.37B | 0.31 | 3.69 | 6.42 | ||
T. Rowe Price Health Sciences | 6.42B | -0.13 | 3.27 | 7.56 | ||
Fidelity Select Health Care | 6.2B | -2.20 | 4.18 | 7.04 | ||
Vanguard Health Care Inv | 5.84B | 0.29 | 3.64 | 6.36 | ||
T. Rowe Price Health Sciences I | 4.61B | -0.06 | 3.40 | - |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 24.89 | 713.71 | -0.21% | |
Novo Nordisk ADR | US6701002056 | 12.25 | 67.35 | -1.20% | |
AstraZeneca ADR | US0463531089 | 10.29 | 70.41 | +0.66% | |
GSK plc DRC | US37733W2044 | 5.63 | 38.66 | -0.67% | |
Gilead | US3755581036 | 5.44 | 107.37 | +0.59% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Sell |
Technical Indicators | Sell | Strong Sell | Strong Sell |
Summary | Strong Sell | Strong Sell | Strong Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review